News

Danny Nguyen, MD, of City of Hope discusses bringing clinical trials to community oncology practices and the latest advances in lung cancer treatment.

Large genomic study shows BRCA2 breast cancers rapidly lose RB1, resisting CDK4/6 therapy; PARP inhibitors may work better and move to first line.

Experts break down second-line CAR T for relapsed DLBCL—who qualifies, what to expect, and why logistics still block access.

During a live event, Ruta Rao, MD, and participants discussed how the redefined HER2 spectrum, including the new HER2-ultra low category, is reshaping first antibody-drug conjugate selection in HR+/HER2– metastatic breast cancer.

An oral combination of sirolimus and domatinostat is being used to treat patients with metastatic osteosarcoma and other sarcomas.

AI-built social posts aim to raise young women’s awareness that alcohol increases breast cancer risk, while a trial tracks drinking habits.

The MonumenTAL-6 study found significant improvement with the combination of teclistamab and talquetamab vs standard regimens in relapsed/refractory multiple myeloma.

The ProstACT SELECT trial demonstrated safety and antitumor activity for TLX591-Tx in a population selected by PSMA expression in metastatic castration-resistant prostate cancer.

The FDA will review the PARP inhibitor/androgen pathway receptor inhibitor combination in metastatic castration-sensitive prostate cancer in the fourth quarter of 2026.

Longer follow-up links ivonescimab plus chemo to stronger survival gains in EGFR-mutant NSCLC worldwide, supporting FDA review after TKI failure.

FDA clears zidesamtinib for previously treated ROS1-positive metastatic NSCLC, showing 44% responses, CNS activity, and manageable safety in ARROS-1 trial.

The NDA for daraxonrasib in PDAC is supported by results from the phase 3 RASolute 302 trial.

Explore second-line options after ICI failure in metastatic ccRCC, featuring TiNivo-2 insights and tivozanib’s tolerability and PFS.

Phase 1/2 SIDNEY interim results show EO2463 boosts CD8 T cells, linking to longer PFS and responses in indolent NHL watch-and-wait patients.

The 100% response rate for the combination was achieved in older patients with locally advanced or metastatic head and neck squamous cell carcinoma.

The ADMIRE study specifically enrolls patients with cutaneous squamous cell carcinoma who would otherwise be excluded from trials due to organ transplant or other immunocompromised state.

Phase 1 TRAVERSE results show that off-the-shelf CD70 CAR T ALLO-316 drives durable responses in refractory clear cell kidney cancer, with manageable safety signals.

Ten-year RELEVANCE results show chemo-free R2 matches immunochemotherapy for advanced follicular lymphoma, with comparable survival and safety.

The ENDURANCE study showed no difference in overall survival between 2 years of lenalidomide and indefinite treatment in standard-risk patients who did not receive autologous stem cell transplant.

The designation for pelareorep was supported by results from the phase 1/2 GOBLET study.

Phase 2 KEYPAD shows pembrolizumab plus denosumab yields 31% responses and 7.5-month PFS in VEGFR-TKI–pretreated clear-cell RCC.

During a live event, Millie Das, MD, and participants discussed how long-term survival data are reshaping first-line treatment selection for patients with PD-L1–negative metastatic non–small cell lung cancer.

Phase 2 data show safusidenib drives deepening responses and durable control in IDH1‑mutant grade 2 glioma, prompting new trials for earlier and post‑vorasidenib use.

In an interview, Joseph Mikhael, MD, MEd, discussed the impact of the approval of subcutaneous isatuximab and its on-body delivery system in multiple myeloma.

TREASURE trial shows adding thoracic radiotherapy to atezolizumab maintenance in ES‑SCLC boosts fatal toxicity without survival gain.

Five-year WSG TP-II results suggest chemo-free endocrine therapy with dual HER2 blockade matches paclitaxel, with fewer severe side effects.

ENHANCE phase 3 results show that magrolimab added to azacitidine failed to boost remission or survival in higher-risk MDS and increased serious toxicity.

Long OMNIVORE follow-up shows select advanced RCC responders stop nivolumab and stay treatment-free for years; salvage ipilimumab adds little.